Study guide
19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching
Key Takeaways Explain This Topic AI
Community Reinforcement and Family Training (CRAFT) engages roughly two-thirds of previously treatment-refusing loved ones, substantially outperforming Al-Anon referral and the confrontational Johnson Institute intervention.
CRAFT teaches concerned significant others to reinforce non-using behavior, withdraw reinforcement of using behavior, practice self-care and use safety planning, and improves the family member's own wellbeing regardless of whether the loved one enters treatment.
Every household containing a person who uses opioids or stimulants should have naloxone, with at least one other person trained to recognize overdose and administer it.
Confrontational intervention models have the weakest evidence and the highest family attrition, and should not be recommended.
42 CFR Part 2 limits what the APRN may disclose to family members, but nothing prevents providing general education and receiving information from them.
Last updated: September 2026
19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching
Quick Answer: CRAFT (Community Reinforcement and Family Training) engages roughly two-thirds of previously treatment-refusing loved ones into treatment — roughly double or triple the rates achieved by Al-Anon facilitation or the confrontational Johnson Institute intervention , and with far lower family dropout. CRAFT also improves the concerned significant other's own depression, anxiety, anger and family functioning regardless of whether the loved one enters treatment. Every household with opioid or stimulant use needs naloxone plus a trained bystander . 42 CFR Part 2 limits disclosure to family, but never limits receiving information or providing general education .
1. Why the Confrontational Model Fails
The televised "intervention" — a surprise confrontation with rehearsed letters and an ultimatum — derives from the Johnson Institute model. In head-to-head trials it engages a minority of loved ones and produces the highest family dropout of the approaches studied, because most families cannot bring themselves to carry it out. It also damages trust in a way that makes later engagement harder.
- Approach Engagement of treatment-refusing loved one Family retention
- CRAFT About two-thirds High
- Al-Anon / Nar-Anon facilitation Roughly one in seven or fewer High; benefits the family member's wellbeing
- Johnson Institute confrontation Roughly one in four, with most families never completing it Lowest
Important nuance: Al-Anon is not a failed intervention — it simply has a different goal. It is designed to help the family member , and it does that well. Its poor engagement numbers reflect that engaging the person who uses substances is not its purpose.
2. What CRAFT Actually Teaches
Component Content
Functional analysis Map the antecedents and consequences of the loved one's use, including the family behaviors that inadvertently reinforce it
Positive reinforcement of non-using behavior Deliver attention, warmth and shared activity when the loved one is not using; be explicit about why
Withdrawing reinforcement of using behavior Step back from the natural consequences without punishing — leave the room calmly rather than argue, decline to cover a missed shift
Communication training Use "I" statements, brief positive requests, partial responsibility and an offer to help, rather than accusation
Self-care Explicit permission and planning for the family member's own health, relationships, work and enjoyment
Safety planning Recognize escalation, plan an exit, know when to involve law enforcement
Treatment-entry preparation Rehearse the invitation and have it ready for the moment of openness, with an appointment available within days
The counterintuitive core of CRAFT: it works by increasing the reward value of not using , not by escalating punishment. Families arrive expecting to be told how to apply consequences and are often relieved to learn the evidence points elsewhere.
3. Overdose Prevention Training for the Household
Teach every household member, not just the patient:
Recognize it. Unresponsive to a sternal rub or shouting; slow, shallow, or absent breathing; gurgling or snoring; blue or grey lips and fingertips; pinpoint pupils.
Call 911. Emphasize that most states have Good Samaritan laws protecting the caller from certain drug-possession charges, and teach what to say: "Someone is not breathing."
Give naloxone. Demonstrate device assembly and administration with a trainer device and have the family member demonstrate back . Intranasal: one spray in one nostril; repeat in the alternate nostril every 2 to 3 minutes if no response.
Rescue breathing. One breath every 5 seconds — hypoxia, not the opioid itself, causes the brain injury.
Stay and monitor. Fentanyl frequently outlasts naloxone; renarcotization is real. Recovery position if breathing resumes and you must step away.
Expect withdrawal. The person may wake agitated, nauseated and angry. Prepare the family for that so they do not interpret it as ingratitude or hesitate next time.
Refill it. Naloxone expires and gets used. Build a refill reminder into the plan.
4. Correcting Family Beliefs
Common belief Evidence-based reframe
"They have to hit rock bottom." There is no evidence that suffering produces recovery; many people die at the bottom. Earlier engagement produces better outcomes.
"Methadone and buprenorphine are just substituting one addiction for another." These medications reduce mortality substantially; a person with stable dosing is not intoxicated and can work, parent and drive.
"If I keep helping, I'm enabling." CRAFT distinguishes reinforcing use from supporting the person; keeping someone alive and connected is not enabling.
"Relapse means treatment failed." Recurrence rates resemble those of other chronic diseases; recurrence signals a need to adjust the plan, not to abandon it.
"We should not talk about it in front of the kids." Age-appropriate honesty reduces children's self-blame; secrecy increases it.
5. Confidentiality Boundaries With Families
42 CFR Part 2 restricts disclosure of patient-identifying information from a Part 2 program. What that does and does not prevent:
The APRN may The APRN may not
Receive information from family without patient consent Confirm or deny that the person is a patient, absent consent
Provide general education about substance use disorders, treatment and naloxone Share diagnosis, treatment plan, attendance or toxicology results without valid consent
Refer family to CRAFT, Al-Anon, Nar-Anon or family therapy Disclose under a subpoena alone — a Part 2 court order is also required
Disclose in a bona fide medical emergency to the extent necessary Treat a general HIPAA consent as authorization for law enforcement or litigation use
Practical move: obtain a written consent early, naming the specific family members and the specific information categories, and revisit it as relationships change. The 2024 Final Rule permits a single broad consent for treatment, payment and health care operations, which simplifies care coordination but still does not authorize disclosure in legal proceedings.